Biotech

OrganiCare Raises a $8.5M Series A to Expand its Natural Feminine Over-the-Counter Healthcare Platform

OrganiCare, the maker of all-natural over the counter healthcare products has announced the closing of an oversubscribed Series A financing of $8.5M after an aggressive 2020 year of growth, which included the launch of a new OTC Genital Herpes product under the FemiClear brand. “We are excited about the growth of OrganiCare,” said Jake Moilanen, General Partner at Seraph Group, and second time investor in…

Gynov Releases Gynositol, A New Supplement Promising Relief for Women with PCOS

Gynov is a company dedicated to pioneering genuine, effective, and targeted solutions to various female health concerns. Beyond the qualitative approach based on robust scientific data, the French company designs products integrated not only into medical care but above all into a holistic vision of human health. Gynov, short for Gynecological Innovation, was founded by Pierre-Yves Mousset MD, in France in 2016. The company’s flagship product…

Organon and ObsEva Enter Global License Agreement for Preterm Labor Treatment

Every year, an estimated 15 million babies are born preterm. Organon, a global women’s health company spun out of Merck and ObsEva, a biopharmaceutical company dedicated to improving women’s reproductive health have now announced that the companies have entered into an agreement whereby Organon will license the global development, manufacturing and commercial rights to ebopiprant (OBE022). Ebopiprant is an investigational, orally active,…

Jeeva Wants to Help Increase Patient Diversity in Clinical Trials

While nearly 40% of Americans belong to a racial or ethnic minority, the base of patients who participate in clinical trials for new drugs skew heavily white—in some cases, 80 to 90 percent. “How,” asks Dr. Harsha Rajasimha, founder and CEO of Jeeva Informatics, “can a drug aimed at the general public be trusted if its effect on other races and ethnicities is…

Evvy Raises a $5M Seed Round for its At-Home Vaginal Microbiome Test Leveraging Metagenomic Sequencing

Evvy, a female-founded startup that aims to build a new understanding of the female body, launches today. Evvy’s first focus is on a critical but often overlooked biomarker: the vaginal microbiome. Evvy is co-founded by Stanford alumni Priyanka Jain and Laine Bruzek and backed by a newly raised seed round of $5 million from General Catalyst, Box Group, Virtue, Human Ventures, G9 Ventures, BBG Ventures, and others. Margo Georgiadis, Executive-in-Residence at General…

Medicines360, a Global Nonprofit Women’s Health Pharmaceutical Organization, Appoints Dr. Tina Raine-Bennett as Chief Executive Officer

Medicines360, a global nonprofit women’s health pharmaceutical organization, has appointed Tina Raine-Bennett, MD, MPH, FACOG, Chief Executive Officer (CEO), effective immediately, following a broad national search. With over 30 years of experience, Dr. Raine-Bennett has an extensive career of expanding research into women’s health and translating that research into clinical practice to improve health outcomes for women. “At a time when women across the globe…

Women’s Health Startup Mammogen Announces a $2M Seed Round and the Debut of its genTRU Liquid Biopsy Platform

Women’s health startup Mammogen has announced the closing of its $2M seed round. The round was oversubscribed by a diverse group of high-net-worth investors, comprising 52% women, members of the LGBTQ+ community, and veterans from the US Armed Forces, according to the company.  “The vast diversity across our investor base is evidence that the world is ready for a truly differentiated women’s health narrative,”…

Daré Bioscience Announces Positive Phase 1 Results for DARE-HRT1 Supporting its Potential as the First Monthly Therapy for both the Vasomotor and Vaginal Symptoms of Menopause

Daré Bioscience has announced positive topline results from its Phase 1 clinical trial of DARE-HRT1. DARE-HRT1 is a novel IVR designed to deliver bio-identical 17β-estradiol and bio-identical progesterone continuously over a 28-day period as part of a hormone therapy (HT) regimen to treat the vasomotor symptoms (VMS) and genitourinary syndrome associated with menopause. The topline data from the study support DARE-HRT1’s potential to…